一线免疫治疗在NMOSD中的疗效与耐受性评估
该回顾性研究纳入136例AQP4或MOG抗体阳性NMOSD患者,比较早期一线使用利妥昔单抗、霉酚酸酯或硫唑嘌呤的疗效与严重感染风险。结果显示利妥昔单抗在降低复发风险上优于霉酚酸酯,且不依赖抗体状态,但三组严重感染事件分布不同。
要点
- 一线利妥昔单抗降低复发风险优于霉酚酸酯(HR 2.74,p=0.020)。
- 利妥昔单抗与硫唑嘌呤的复发风险无显著差异(HR 2.13,p=0.17)。
- 霉酚酸酯组报告9例严重感染事件,利妥昔单抗组6例,硫唑嘌呤组无。
核心结论
- 一线使用利妥昔单抗在抑制NMOSD临床活动方面似乎比霉酚酸酯更有效,且独立于抗体状态。
研究设计与样本
- 回顾性纳入136例AQP4或MOG抗体阳性NMOSD患者,均在发病3年内开始一线免疫抑制剂治疗。
主要发现
- 与利妥昔单抗组相比,霉酚酸酯组复发风险更高(HR 2.74 [1.17-6.40];p=0.020),已校正年龄、性别、抗体状态、病程、治疗前ARR、皮质类固醇使用及复发部位。
- 利妥昔单抗组与硫唑嘌呤组复发风险无差异(HR 2.13 [0.72-6.28];p=0.17)。
- 抗体状态与免疫抑制剂治疗之间未发现交互作用。
- 利妥昔单抗组ARR低于霉酚酸酯组(p=0.039),但与硫唑嘌呤组无差异。
- 严重感染事件:霉酚酸酯组9例,利妥昔单抗组6例,硫唑嘌呤组0例。
关键数值与推荐
- 利妥昔单抗组与霉酚酸酯组的ARR差异有统计学意义(p=0.039)。
临床怎么用
- 对于AQP4或MOG抗体阳性NMOSD患者,早期一线可优先考虑利妥昔单抗以降低复发风险。
- 使用霉酚酸酯时需关注严重感染事件的发生。
局限性
- 本研究为回顾性设计,证据等级为Class III。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and the risk of severe infectious events of immunosuppressive agents used early as first-line therapy in patients with neuromyelitis optica spectrum disorder (NMOSD). METHODS: We retrospectively included patients with NMOSD and a seropositive status for aquaporin 4 or myelin oligodendrocyte glycoprotein antibodies beginning first-line immunosuppressants within 3 years after the disease onset. The main outcome was occurrence of relapse after the initiation of immunosuppressants; the secondary outcome was the annual relapse rate (AAR). RESULTS: A total of 136 patients were included: 62 (45.6%) were treated with rituximab (RTX), 42 (30.9%) with mycophenolate mofetil (MMF), and 23 (16.9%) with azathioprine (AZA). Compared with RTX-treated patients, the risk of relapse was higher among MMF-treated patients (hazard ratio [HR], 2.74 [1.17-6.40]; p = 0.020) after adjusting for age at disease onset, sex, antibody status, disease duration, ARR before treatment, corticosteroid intake, and relapse location. We did not observe any difference between RTX-treated and AZA-treated patients (HR, 2.13 [0.72-6.28]; p = 0.17). No interaction was found between the antibody status and immunosuppressive treatments. ARR was lower with RTX than with MMF (p = 0.039), but no difference was observed with AZA. We observed 9 serious infectious events with MMF, 6 with RTX, and none with AZA. CONCLUSIONS: The use of first-line RTX in NMOSD appears more effective than MMF in suppressing clinical activity, independent of the antibody status. CLASSIFICATION OF EVIDENCE: That study provides Class III evidence that for patients with NMOSD, first-line RTX is superior to MMF to reduce the risk of relapse.
引用
- Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020. PMID: 32170036. doi:10.1212/WNL.0000000000009245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。